{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T17:01:34Z","timestamp":1771434094794,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40263-025-01252-x","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T15:53:15Z","timestamp":1765813995000},"page":"481-490","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing Cognitive Function over Time in Patients with Refractory Chronic Migraine Who Received Ketamine Infusions: A Prospective, Observational Study"],"prefix":"10.1007","volume":"40","author":[{"given":"Marianna","family":"Vinokur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Schwenk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sawsan","family":"Alabad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winston","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiangkuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6421-6594","authenticated-orcid":false,"given":"Michael J.","family":"Marmura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"issue":"9","key":"1252_CR1","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/j.1526-4610.2010.01764.x","volume":"50","author":"SD Silberstein","year":"2010","unstructured":"Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010;50(9):1499\u2013506.","journal-title":"Headache"},{"key":"1252_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.psychres.2018.08.078","volume":"269","author":"MH Chen","year":"2018","unstructured":"Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, et al. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study. Psychiatry Res. 2018;269:207\u201311.","journal-title":"Psychiatry Res"},{"issue":"5","key":"1252_CR3","first-page":"521","volume":"43","author":"SP Cohen","year":"2018","unstructured":"Cohen SP, Bhatia A, Buvanendran A, Schwenk ES, Wasan AD, Hurley RW, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists. Reg Anesth Pain Med. 2018;43(5):521\u201346.","journal-title":"Reg Anesth Pain Med"},{"issue":"4","key":"1252_CR4","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","volume":"47","author":"RM Berman","year":"2000","unstructured":"Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351\u20134.","journal-title":"Biol Psychiatry"},{"issue":"8","key":"1252_CR5","first-page":"875","volume":"43","author":"ES Schwenk","year":"2018","unstructured":"Schwenk ES, Dayan AC, Rangavajjula A, Torjman MC, Hernandez MG, Lauritsen CG, et al. Ketamine for refractory headache: a retrospective analysis. Reg Anesth Pain Med. 2018;43(8):875\u20139.","journal-title":"Reg Anesth Pain Med"},{"key":"1252_CR6","doi-asserted-by":"crossref","unstructured":"Schwenk ES, Torjman MC, Moaddel R, Lovett J, Katz D, Denk W, et al. Ketamine for refractory chronic migraine: an\u00a0observational pilot study and metabolite analysis. J Clin Pharmacol. 2021;61(11):1421\u20139.","DOI":"10.1002\/jcph.1920"},{"issue":"2","key":"1252_CR7","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/head.13013","volume":"57","author":"JL Pomeroy","year":"2017","unstructured":"Pomeroy JL, Marmura MJ, Nahas SJ, Viscusi ER. Ketamine infusions for treatment refractory headache. Headache. 2017;57(2):276\u201382.","journal-title":"Headache"},{"issue":"4910","key":"1252_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1126\/science.2660263","volume":"244","author":"JW Olney","year":"1989","unstructured":"Olney JW, Labruyere J, Price MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989;244(4910):1360\u20132.","journal-title":"Science"},{"key":"1252_CR9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-444-64196-0.00005-4","volume":"166","author":"R Leech","year":"2019","unstructured":"Leech R, Smallwood J. The posterior cingulate cortex: insights from structure and function. Handb Clin Neurol. 2019;166:73\u201385.","journal-title":"Handb Clin Neurol"},{"key":"1252_CR10","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.neubiorev.2019.04.016","volume":"107","author":"TP Todd","year":"2019","unstructured":"Todd TP, Fournier DI, Bucci DJ. Retrosplenial cortex and its role in cue-specific learning and memory. Neurosci Biobehav Rev. 2019;107:713\u201328.","journal-title":"Neurosci Biobehav Rev"},{"issue":"4","key":"1252_CR11","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1007\/s00213-006-0572-3","volume":"188","author":"CJ Morgan","year":"2006","unstructured":"Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology. 2006;188(4):408\u201324.","journal-title":"Psychopharmacology"},{"issue":"3","key":"1252_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/sj.npp.1300642","volume":"30","author":"LM Rowland","year":"2005","unstructured":"Rowland LM, Astur RS, Jung RE, Bustillo JR, Lauriello J, Yeo RA. Selective cognitive impairments associated with NMDA receptor blockade in humans. Neuropsychopharmacology. 2005;30(3):633\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1252_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1360-0443.2009.02761.x","volume":"105","author":"CJ Morgan","year":"2010","unstructured":"Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 2010;105(1):121\u201333.","journal-title":"Addiction"},{"key":"#cr-split#-1252_CR14.1","unstructured":"IHS Classification ICHD-3. [cited 2018 February 16]"},{"key":"#cr-split#-1252_CR14.2","unstructured":"Available from: https:\/\/www.ichd-3.org\/8-headache-attributed-to-a-substance-or-its-withdrawal\/8-2-medication-overuse-headache-moh\/8-2-4-opioid-overuse-headache\/. Accessed 12 Mar 2025."},{"issue":"6","key":"1252_CR15","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/j.1526-4610.2008.01132.x","volume":"48","author":"EA Schulman","year":"2008","unstructured":"Schulman EA, Lake AE 3rd, Goadsby PJ, Peterlin BL, Siegel SE, Markley HG, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache. 2008;48(6):778\u201382.","journal-title":"Headache"},{"issue":"22","key":"1252_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"1252_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1177\/1460458214556373","volume":"22","author":"A Abdolahi","year":"2016","unstructured":"Abdolahi A, Bull MT, Darwin KC, Venkataraman V, Grana MJ, Dorsey ER, et al. A feasibility study of conducting the Montreal Cognitive Assessment remotely in individuals with movement disorders. Health Inform J. 2016;22(2):304\u201311.","journal-title":"Health Inform J"},{"issue":"8","key":"1252_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1177\/1357633X19890788","volume":"27","author":"JE Chapman","year":"2021","unstructured":"Chapman JE, Cadilhac DA, Gardner B, Ponsford J, Bhalla R, Stolwyk RJ. Comparing face-to-face and videoconference completion of the Montreal Cognitive Assessment (MoCA) in community-based survivors of stroke. J Telemed Telecare. 2021;27(8):484\u201392.","journal-title":"J Telemed Telecare"},{"issue":"7","key":"1252_CR19","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1089\/tmj.2019.0134","volume":"26","author":"K Iiboshi","year":"2020","unstructured":"Iiboshi K, Yoshida K, Yamaoka Y, Eguchi Y, Sato D, Kishimoto M, et al. A validation study of the remotely administered Montreal Cognitive Assessment Tool in the elderly Japanese population. Telemed J E Health. 2020;26(7):920\u20138.","journal-title":"Telemed J E Health"},{"issue":"1","key":"1252_CR20","volume":"13","author":"MJ Katz","year":"2021","unstructured":"Katz MJ, Wang C, Nester CO, Derby CA, Zimmerman ME, Lipton RB, et al. T\u2010MoCA: a valid phone screen for cognitive impairment in diverse community samples. Alzheimer\u2019s Dement Diagn Assess Dis Monit. 2021;13(1):e12144.","journal-title":"Alzheimer's Dement Diagn Assess Dis Monit"},{"issue":"4","key":"1252_CR21","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1111\/jgs.12742","volume":"62","author":"P Julayanont","year":"2014","unstructured":"Julayanont P, Brousseau M, Chertkow H, Phillips N, Nasreddine ZS. Montreal Cognitive Assessment Memory Index Score (MoCA-MIS) as a predictor of conversion from mild cognitive impairment to Alzheimer\u2019s disease. J Am Geriatr Soc. 2014;62(4):679\u201384.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1252_CR22","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/STROKEAHA.112.673384","volume":"44","author":"ST Pendlebury","year":"2013","unstructured":"Pendlebury ST, Welch SJ, Cuthbertson FC, Mariz J, Mehta Z, Rothwell PM. Telephone assessment of cognition after transient ischemic attack and stroke: modified telephone interview of cognitive status and telephone Montreal Cognitive Assessment versus face-to-face Montreal Cognitive Assessment and neuropsychological battery. Stroke. 2013;44(1):227\u20139.","journal-title":"Stroke"},{"key":"1252_CR23","volume":"6","author":"E Lindvall","year":"2024","unstructured":"Lindvall E, Abzhandadze T, Quinn TJ, Sunnerhagen KS, Lundstrom E. Is the difference real, is the difference relevant: the minimal detectable and clinically important changes in the Montreal Cognitive Assessment. Cereb Circ Cogn Behav. 2024;6:100222.","journal-title":"Cereb Circ Cogn Behav."},{"issue":"2","key":"1252_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1046\/j.1468-2982.1999.019002107.x","volume":"19","author":"WF Stewart","year":"1999","unstructured":"Stewart WF, Lipton RB, Kolodner K, Liberman J, Sawyer J. Reliability of the migraine disability assessment score in a population-based sample of headache sufferers. Cephalalgia. 1999;19(2):107\u201314 (discussion 74).","journal-title":"Cephalalgia"},{"issue":"3","key":"1252_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M. Validation of the headache impact test (HIT-6) across episodic and chronic migraine. Cephalalgia. 2011;31(3):357\u201367.","journal-title":"Cephalalgia"},{"issue":"12","key":"1252_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/rapm-2022-104223","volume":"48","author":"H Yuan","year":"2023","unstructured":"Yuan H, Natekar A, Park J, Lauritsen CG, Viscusi ER, Marmura MJ. Real-world study of intranasal ketamine for use in patients with refractory chronic migraine: a retrospective analysis. Reg Anesth Pain Med. 2023;48(12):581\u20137.","journal-title":"Reg Anesth Pain Med"},{"issue":"6","key":"1252_CR27","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.acn.2007.05.005","volume":"22","author":"SP Koffler","year":"2007","unstructured":"Koffler SP, Hampstead BM, Irani F, Tinker J, Kiefer RT, Rohr P, et al. The neurocognitive effects of 5 day anesthetic ketamine for the treatment of refractory complex regional pain syndrome. Arch Clin Neuropsychol. 2007;22(6):719\u201329.","journal-title":"Arch Clin Neuropsychol"},{"key":"1252_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.neubiorev.2020.11.020","volume":"120","author":"H Gill","year":"2021","unstructured":"Gill H, Gill B, Rodrigues NB, Lipsitz O, Rosenblat JD, El-Halabi S, et al. The effects of ketamine on cognition in treatment-resistant depression: a systematic review and priority avenues for future research. Neurosci Biobehav Rev. 2021;120:78\u201385.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"1252_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s10194-022-01486-w","volume":"23","author":"C Gonzalez-Mingot","year":"2022","unstructured":"Gonzalez-Mingot C, Gil-Sanchez A, Canudes-Solans M, Peralta-Moncusi S, Solana-Moga MJ, Brieva-Ruiz L. Preventive treatment can reverse cognitive impairment in chronic migraine. J Headache Pain. 2022;23(1):121.","journal-title":"J Headache Pain"},{"issue":"5037","key":"1252_CR30","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1126\/science.1835799","volume":"254","author":"JW Olney","year":"1991","unstructured":"Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254(5037):1515\u20138.","journal-title":"Science"},{"issue":"1","key":"1252_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF00386248","volume":"87","author":"RN Auer","year":"1994","unstructured":"Auer RN, Coulter KC. The nature and time course of neuronal vacuolation induced by the N-methyl-D-aspartate antagonist MK-801. Acta Neuropathol. 1994;87(1):1\u20137.","journal-title":"Acta Neuropathol"},{"issue":"1\u20132","key":"1252_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/0006-8993(95)00842-E","volume":"696","author":"AS Fix","year":"1995","unstructured":"Fix AS, Wozniak DF, Truex LL, McEwen M, Miller JP, Olney JW. Quantitative analysis of factors influencing neuronal necrosis induced by MK-801 in the rat posterior cingulate\/retrosplenial cortex. Brain Res. 1995;696(1\u20132):194\u2013204.","journal-title":"Brain Res"},{"issue":"87","key":"1252_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ntt.2021.106993","volume":"1","author":"PJ Morris","year":"2021","unstructured":"Morris PJ, Burke RD, Sharma AK, Lynch DC, Lemke-Boutcher LE, Mathew S, et al. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. Neurotoxicol Teratol. 2021;1(87):106993.","journal-title":"Neurotoxicol Teratol"},{"key":"1252_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2014.00149","volume":"5","author":"CJ Morgan","year":"2014","unstructured":"Morgan CJ, Dodds CM, Furby H, Pepper F, Fam J, Freeman TP, et al. Long-term heavy ketamine use is associated with spatial memory impairment and altered hippocampal activation. Front Psychiatry. 2014;5:149.","journal-title":"Front Psychiatry"},{"issue":"1","key":"1252_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1080\/14740338.2021.1949454","volume":"21","author":"J Van Amsterdam","year":"2022","unstructured":"Van Amsterdam J, Van Den Brink W. Harm related to recreational ketamine use and its relevance for the clinical use of ketamine. A systematic review and comparison study. Expert Opin Drug Saf. 2022;21(1):83\u201394.","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"1252_CR36","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, Bedirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"1252_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-017-0779-1","volume":"18","author":"SH Lee","year":"2017","unstructured":"Lee SH, Kang Y, Cho SJ. Subjective cognitive decline in patients with migraine and its relationship with depression, anxiety, and sleep quality. J Headache Pain. 2017;18(1):77.","journal-title":"J Headache Pain"},{"issue":"1\u20132","key":"1252_CR38","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0006-8993(97)01247-X","volume":"781","author":"V Jevtovic-Todorovic","year":"1998","unstructured":"Jevtovic-Todorovic V, Wozniak DF, Powell S, Nardi A, Olney JW. Clonidine potentiates the neuropathic pain-relieving action of MK-801 while preventing its neurotoxic and hyperactivity side effects. Brain Res. 1998;781(1\u20132):202\u201311.","journal-title":"Brain Res"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01252-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01252-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T16:03:13Z","timestamp":1771430593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01252-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1252"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01252-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Vinokur has nothing to disclose. Dr. Schwenk has nothing to disclose. Dr. Alabad has nothing to disclose. Dr. Hamilton has nothing to disclose. Within the past 24 months, Dr. Yuan has received funding from the American Headache Society; institutional support for serving as an investigator from Teva, AbbVie, Ipsen, Parema, Shiratronics, Johnson & Johnson, Pfizer, and Lundbeck; consultant\/advisory board fees from Salvia, Pfizer, AbbVie, and Cerenovus; and royalties from Cambridge University Press and MedLink Neurology. Dr. Fallon has nothing to disclose. Within the last 24 months, Dr. Marmura has received honoraria for consultations from Lundbeck. He has received research funding for his role as principal investigator from Teva, Lundbeck, and AbbVie.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Marianna Vinokur: Conceptualization, data curation, investigation, methodology, formal analysis, validation, writing\u2014original draft, and writing\u2014review and editing. Eric Schwenk: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, supervision, writing\u2014original draft, and writing\u2014review and editing. Sawsan Alabad: Data curation, investigation, methodology, and writing\u2014review and editing. Winston Hamilton: Data curation, investigation, methodology, and writing\u2014review and editing. Hsiangkuo Yuan: Conceptualization, data curation, formal analysis, investigation, methodology, project administration, supervision, validation, writing\u2014original draft, and writing\u2014review and editing. Samuel Fallon: Data curation, investigation, and writing\u2014review and editing. Michael Marmura: Conceptualization, data curation, funding acquisition, investigation, methodology, project administration, validation, writing\u2014original draft, and writing\u2014review and editing. All authors have read and approve the final submitted manuscript, and agree to be accountable for the work presented here.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors' Contributions"}},{"value":"Data are available upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"This study was approved by the Thomas Jefferson University institutional review board on April 22, 2021 (Control #21D.412). All patients provided written informed consent. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments, with the exception that this study was not registered due to its observational design.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study via either telephone or in person screening. All participants signed written consents prior to study participation. All signed written consent records are stored in Thomas Jefferson University Hospital.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}